PharmaVoice

DECEMBER 1, 2022

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

122

122

IDStewardship

OCTOBER 27, 2022

In this article an infectious diseases pharmacist discusses antibiotic myths. Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP. Article posted 27 October 2022. Have you ever seen the show MythBusters on the Discovery Channel? Well this blog post is not nearly as cool as that show, but it may be a fun read at least! Here are 15 antibiotic myths to beware… Myth 1: Stopping antibiotic courses early leads to antibiotic resistance.

Labelling 364

Labelling FDA 364

Pharmacy Times

NOVEMBER 14, 2022

Despite evidence of a higher risk of myocarditis or pericarditis with COVID-19 vaccination, immunization should still be recommended because the benefits likely outweigh the harms, study shows.

Vaccines 182

Vaccines Immunization 182

Pharma Mirror

DECEMBER 16, 2022

The COVID-19 pandemic challenged researchers to discover life-saving treatments at an unprecedented pace. While these researchers rose to the occasion by discovering drugs faster than ever before, variants continue to challenge the world in addressing COVID-19. New innovations in computer-aided drug discovery tools could dramatically accelerate the study of new variants.

105

105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

PharmExec

AUGUST 10, 2022

The technology is not just about digital enablement anymore.

141

141

Pharmaceutical Technology

NOVEMBER 25, 2022

Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’. In this survey-based report tracker, digital media was prioritised as a top current investment target, with 53% of surveyed respondents confirming that their companies are currentl

Pharmaceutical Companies 145

Pharmaceutical Companies Pharmaceutical Companies 145

Pharmafile

DECEMBER 6, 2022

San Francisco, US-based Nkarta have been assessing the power of natural killer (NK) cells in oncology treatments. The treatment is as-yet unproven but appears hopefully at this early stage. Nkarta has just reported results from an early-stage trial of its CAR-NK therapies, which looks likely to generate enthusiasm to this area of research. read more.

106

106

Pharma Marketing Network

MARCH 25, 2022

Members of a multidisciplinary care team may include physicians, nurses, pharmacists, radiologists, dieticians…the list goes on. But one key member is often omitted: the patient’s caregiver. With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. Although the caregiver is seen as an extension of the patient and their role is not strictly defined, they are informal members of the front-line care team.

Labelling 98

Labelling FDA 98

PharmExec

DECEMBER 14, 2022

Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.

136

136

PhRMA

SEPTEMBER 20, 2022

World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful and unnecessary decision to do the same for COVID-19 vaccines. This is referred to as the TRIPS waiver.

Vaccines 306

Vaccines 306

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Topics

DECEMBER 9, 2022

A group of pharmacists rose to the occasion to help a man having a medical emergency aboard a recent United flight bound for Newark, New Jersey.

275

275

IDStewardship

DECEMBER 1, 2022

In this article a pharmacist with advanced training and experience in infectious diseases discusses five things pharmacists should know about ventilator associated pneumonia (VAP). Authored By: Lucia Rose, PharmD, BCIDP. Article Posted 1 December 2022. It was the fall of 2009; I was a proud PGY-1 resident at UMass Medical Center rounding with a large team in the ICU.

Hospitals 348

Hospitals 348

Pharmacy Times

NOVEMBER 7, 2022

A session presenter at the ASCP 2022 Annual Meeting addresses research investigating the value of preventative treatments when patients have a limited life expectancy.

181

181

STAT

DECEMBER 20, 2022

Lots of people struggle to get enough sleep — and the responsibility for fixing the problem tends to fall on the individual. Experts offer advice like reducing screen time, exercising more, or just going to bed earlier in the evening. But many restless nights can’t be solved with blackout curtains, ear plugs, or other typical suggestions.

145

145

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

DECEMBER 28, 2022

XBB COVID variant presents a unique threat: study. fdiamond. Wed, 12/28/2022 - 11:11.

145

145

pharmaphorum

DECEMBER 19, 2022

A collaboration between academic centres in the UK has won government funding for a digital approach to dysfunctional breathing or dyspnoea, a symptom that affects around 10% of the population. The Engineering and Physical Sciences Research Council (EPSRC) has set aside £400,000 (almost $490,000) for the project, which will help fund work at the Universities of Plymouth, Salford and Stirling, and the Glasgow School of Art.

145

145

IDStewardship

NOVEMBER 13, 2022

On this webpage you will find “The Bug Name Emoji Game” which is just like “ The Drug Name Emoji Game ” and meant to be a fun medical emoji puzzle game for people who deal with different types of microbial pathogens. Simply use the emoji symbols to decipher the corresponding organism name! These puzzles have been developed by Dr.

334

334

PhRMA

NOVEMBER 15, 2022

You are probably reading a lot about a surge of cases of respiratory viruses like respiratory syncytial virus (RSV), influenza (the flu) and SARS-CoV-2, which causes COVID-19. The triple threat of these highly contagious respiratory viruses circulating simultaneously is causing a ripple of effects on patients, health care providers and our health care system as a whole.

Vaccines 302

Vaccines 302

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

PhRMA

OCTOBER 5, 2022

America relies on the U.S. Food & Drug Administration (FDA) to keep pace with the scientific advancements happening every day in labs across the country. That’s why the recently enacted Prescription Drug User Fee Act (PDUFA VII) and Biosimilar User Fee Act (BsUFA III) are both great news for biopharmaceutical innovation and for patients. With these programs reauthorized for another five years, the FDA can continue doing its vital work reviewing medicines.

FDA 302

FDA 302

PhRMA

NOVEMBER 16, 2022

There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that’s at the pharmacy counter. A new report reveals how this harmful tactic leads to higher costs for patients.

Insurance 298

Insurance 298

PhRMA

OCTOBER 27, 2022

PhRMA is proud to announce the release of its first ever chart pack on health equity. This chart pack contains information on health equity in three sections: (1) A Snapshot of Health Disparities in America, (2) Inequities in Access to Screenings and Medicines Allow Health Disparities to Persist, and (3) PhRMA’s Commitment to Building a More Equitable Health Care System for All.

297

297

PhRMA

NOVEMBER 29, 2022

What is TRIPS?

Vaccines 293

Vaccines 293

PhRMA

SEPTEMBER 16, 2022

Guess what? The 340B program grew, yet again, hitting a whopping $43.9 billion in sales at the discounted 340B price in 2021. But there has not been evidence of corresponding growth in care provided to vulnerable patients at 340B covered entities. And making matters worse, fresh data show that 340B may actually be driving up costs for some patients and our health care system as whole.

291

291

PhRMA

OCTOBER 19, 2022

What is Long COVID?

Vaccines 290

Vaccines 290

PhRMA

NOVEMBER 9, 2022

The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was a political and ineffective measure that does not address the true barriers to vaccine equity. Now, some are pushing to extend this harmful waiver to COVID-19 treatments, even though production exceeds demand for treatments, including for the most effective antivirals and monoclonal antibodies.

Vaccines 289

Vaccines 289

PhRMA

DECEMBER 15, 2022

Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group (BRG) found that nearly 36% of all Medicare Part B therapy sales occurred at 340B hospitals in 2021 , up nearly 17 percentage points since 2012, meaning care is moving from physician offices and non-340B hospitals to 340B hospitals.

Hospitals 286

Hospitals 286

PhRMA

SEPTEMBER 23, 2022

September is National Sickle Cell Awareness Month and a time for us to underscore the biopharmaceutical industry’s ongoing commitment to improve the lives of patients, families and communities affected by sickle cell disease.

276

276

PhRMA

OCTOBER 4, 2022

Each first week of October, Americans all across the country take time to reflect on an issue which is increasingly recognized as impacting everyone, whether it be directly as it does me, or indirectly through a family member or friend: mental illness. Mental Illness Awareness Week is an opportunity to raise awareness about the impacts of mental illness and to better understand and educate communities about what it means to face a mental illness, deal with significant moments of stress throughou

Insurance 272

Insurance 272

PhRMA

OCTOBER 26, 2022

A survey of more than 5,000 Americans conducted with Ipsos found that nearly 40% of insured Americans struggle to understand what their health insurance covers.

Insurance 265

Insurance 265

PhRMA

DECEMBER 1, 2022

The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the biopharmaceutical ecosystem are its researchers. Each day, in labs across the country, these individuals work tirelessly on the front lines of research and development to help bring novel medicines to patients.

264

264

PhRMA

SEPTEMBER 12, 2022

As we’ve discussed on this blog before, timely reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA) is critical to sustaining the U.S. Food and Drug Administration’s (FDA) ability to keep pace with the number of innovative drugs, biologics and biosimilars entering the regulatory review pipeline.

FDA 265

FDA 265

PhRMA

SEPTEMBER 12, 2022

Health care affordability is not the only hurdle facing patients, according to PhRMA’s third Patient Experience Survey (PES). The latest PES report exposes another crucial problem: the frustration and confusion people have around how to use their coverage. Administrative hurdles and other barriers imposed by health insurers and pharmacy benefit managers (PBMs), such as time-consuming paperwork or prior authorization, are a challenge for many insured Americans, including more vulnerable communiti

Insurance 264

Insurance 264

IDStewardship

OCTOBER 10, 2022

In this article a pharmacist with specialized training in infectious diseases discusses five key areas of study to master in the field of antimicrobial pharmacotherapy, to become an antibiotic ninja. Authored By: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP. Article posted 11 October 2022. It is commonplace for learners such as students and residents to struggle with infectious diseases pharmacotherapy.

263

263